NCT02128230 — drugset

Summary

The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.

Timeline

Start: 2014-06-10
Primary completion: 2019-02-19
Completion: 2019-02-19

Publications

Pawlyn C. High-risk myeloma: a challenge to define and to determine the optimal treatment. Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22. No abstract available.
Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carfilzomib	Other / unclassified	20 mg/m2	Intravenous
Subject	Carfilzomib	Other / unclassified	27 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	7.5 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	10 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	75 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	100 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	400 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	12 mg	Oral
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Doxorubicin	Other / unclassified	7.5 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	10 mg/m2	Intravenous
Subject	Etoposide	Small molecule	30 mg/m2	Intravenous
Subject	Etoposide	Small molecule	40 mg/m2	Intravenous
Subject	Etoposide	Small molecule	60 mg/m2	Intravenous
Subject	Etoposide	Small molecule	80 mg/m2	Intravenous
Subject	Melphalan	Small molecule	5 mg/m2	Intravenous
Subject	Melphalan	Small molecule	10 mg/m2	Intravenous
Subject	Melphalan	Small molecule	20 mg/m2	Intravenous
Subject	Thalidomide	Other / unclassified	50 mg	Oral
Subject	Thalidomide	Other / unclassified	100 mg	Oral
Subject	Thalidomide	Other / unclassified	200 mg	Oral
Background	filgrastim	Protein / enzyme biologic	10 ug/kg	Subcutaneous

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Summary

Timeline

Publications

Drugs

Indications